Overview

• Lyell Q3 adjusted net loss beats analyst expectations

• Company acquired global rights to LYL273, a GCC-targeted CAR T-cell product

• Initiated PiNACLE - H2H Phase 3 trial for aggressive large B-cell lymphoma

Outlook

• Company expects to begin PiNACLE – H2H trial enrollment by early 2026

• Lyell anticipates LYL273 Phase 1 trial data update in H1 2026

• Current cash expected to support pipeline advancement into 2027

Result Drivers

• LESS R&D EXPENSES: Research and development expenses were $28.2 million for the third quarter ended September 30, 2025, compared to $39.5 million for the same period in 2024.

• LESS G&A EXPENSES: General and administrative expenses were $10.7 million for the third quarter ended September 30, 2025, compared to $11.8 million for the same period in 2024.

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", 1 "hold" and 1 "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy."

• Wall Street's median 12-month price target for Lyell Immunopharma Inc is $12.00, about 43.7% below its November 11 closing price of $17.25

Press Release: ID:nGNXbJ7NZf

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)